Illustrative image – not actual.Sun Pharmaceutical Industries is planning to acquire Ranbaxy Laboratories in a $3.2 billion (approx Rs 19,302.4 crore) all-share deal.
Under the terms of the agreed deal, Ranbaxy shareholders will get 0.8 of a Sun Pharmaceutical share for each Ranbaxy share they own. The deal values Ranbaxy shares at Rs 457 apiece, representing an 18 per cent premium to their 30-day volume weighted average share.
Ranbaxy -- in which 63.4 per cent shares is owned by Japan's Daiichi Sankyo Co -- is banned from exporting drug ingredients to the US Sun Pharmaceutical's Karkhadi plant and is also barred by the US Food and Drug Administration, from shipping products .
